The phase 2 EVITA randomized trial gave patients with precancerous or early blood cancers 1,000 mg oral vitamin C daily for one year or placebo. Vitamin C recipients had fewer adverse events and cytokine shifts linked to better outcomes; abnormal cell expansion did not differ significantly, but expl